Related Experiment Video
Updated: Jun 23, 2026
10:02
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Human trials for neurodegenerative disease.
Claire M Kelly1, O J Handley, A E Rosser
1Brain Repair Group, School of Biosciences, Cardiff, UK.
Methods in Molecular Biology (Clifton, N.J.)
|April 21, 2009
Summary
Cell-based therapies offer hope for neurodegenerative diseases like Parkinson's by replacing lost neurons. Early trials highlight the critical importance of robust clinical trial design for successful neural transplantation.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Neurology
Background:
- Most neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and stroke, lack effective disease-modifying treatments.
- Cell-based therapies aim to replace neurons or glia lost due to disease progression.
- Functional integration of transplanted cells is crucial for reconstructing neural circuitry.
Purpose of the Study:
- To explore the potential of cell-based therapies for neurodegenerative diseases.
- To examine the history and methodology of neural transplantation trials.
- To address challenges and improve future clinical trial design in neurodegenerative disease treatment.
Main Methods:
- Review of historical clinical trials in Parkinson's disease using primary human fetal tissue.
- Analysis of ongoing neural transplantation trials in Huntington's disease.
- Examination of methodological issues in the structure and implementation of clinical trials.
Main Results:
- Early clinical trials for Parkinson's disease commenced in the 1980s.
- Disappointing outcomes in later controlled Parkinson's disease trials underscored methodological limitations.
- Neural transplantation trials are currently underway for Huntington's disease.
Conclusions:
- Cell-based therapies represent a promising avenue for treating neurodegenerative conditions.
- Methodological rigor in clinical trial design is paramount for the success of neural transplantation therapies.
- Further research and refined trial structures are needed to optimize cell-based treatments for neurological disorders.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...